Sun Pharmaceutical Industries shares reached a 52-week high after receiving ANVISA approval in Brazil for its semaglutide injection. This launch, planned in partnership with Hypera Pharma, targets a $413 million diabetes treatment market. The company is also progressing with its $11.75 billion acquisition of Organon & Co.
Sun Pharmaceutical Industries shares touched a new 52-week high on Thursday following the announcement of regulatory clearance in Brazil. The Brazilian Health Regulatory Agency, known as ANVISA, has approved the company’s semaglutide injection, a treatment designed for adults managing Type 2 diabetes. Following the news, the stock rose 1.36% to ₹2,017 on the BSE, bringing the company's total market valuation to over ₹4.82 lakh crore.
Expanding Footprint in Latin America
The approved medication will be introduced in a pre-filled, multi-dose pen format with two dosage strengths, 2 mg/1.5 mL and 4 mg/3 mL. The company plans to initiate a rollout in the country shortly through a partnership with Hypera Pharma, a local pharmaceutical player. According to data from IQVIA for the period ending June 2026, the Brazilian market for this specific injectable treatment is valued at approximately $413 million. This approval marks a strategic effort by the company to increase its presence in the Latin American diabetes care sector.
Strategic Growth and Acquisition Progress
Beyond the product launch in Brazil, the company is moving forward with its broader global expansion strategy. Shareholders of Organon & Co. recently voted in favor of the acquisition proposal by Sun Pharmaceutical Holdings USA, a subsidiary of the Indian pharma giant. This all-cash deal, valued at $11.75 billion, was first announced in April and remains subject to standard closing conditions and further regulatory checks.
If the acquisition is completed as planned in early 2027, the combined entity is projected to generate annual revenues of nearly $12.4 billion. This would move Sun Pharma into the top 25 global pharmaceutical companies by revenue. Furthermore, the merger is expected to strengthen the company’s competitive position in specialized segments, specifically placing it among the top three globally in women's health and the top seven in the biosimilars market.
Investor Monitorables
For shareholders and market observers, the key focus areas remain the pace of the product rollout in Brazil and the eventual integration of the Organon business. While the current stock performance reflects positive sentiment, investors may track the progress of the $11.75 billion acquisition through 2027, as it involves significant capital allocation and potential changes to the company's debt profile and global operating structure. Ongoing regulatory updates regarding the closing of the Organon deal will be the next major milestone for the company’s long-term growth strategy.